LBA002 Targeting GSPT1 by a novel cereblon E3 ligase modulator for the treatment of Acute Lymphoblastic Leukemia. Fatemeh Keramatnia, St. Jude Children's Research Hospital, Memphis, TN

LBA003 Erdafitinib in patients with tumors harboring FGFR gene mutations or fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2. Alain C. Mita, Cedars-Sinai Medical Center, Los Angeles, CA

LBA004 Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer. Gerald Gavory, Mone Rosa Therapeutics AG, Basel, Switzerland

LBA005 Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors. Ryan J. Hansen, Boundless Bio, La Jolla, CA

LBA006 Identification of novel, tumor specific pHLA targets recognized by TILs from CPI responders in a high-throughput, high-diversity pHLA library screening platform (3T-TRACE). Hans-Peter Gerber, 3T Biosciences, South San Francisco, CA

LBA007 Discovery and characterization of oncogenic KRAS:RAF1 conformational modulators with in vitro and in vivo MAPK inhibition. Hong Lin, Quanta Therapeutics, Inc., Malvern, PA

LBA008 CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies. Archie N. Tse, CStone Pharmaceuticals, Shanghai, China (Mainland)

LBA009 Orally available ENPP1 inhibitor, TXN10128, restores STING activation in tumor microenvironment and confers anti-tumor responses in combination with immune checkpoint blockade. Sungjoon Kim, TXINNO Bioscience inc., Yongin, Republic of Korea,

LBA010 Therapeutic stimulation of nucleic acid receptor RIG-I enhances efficacy of kinase inhibitor treatment in oncogene-driven tumors. Johannes Brägelmann, University of Cologne, Cologne, Germany

LBA011 Discovery of combination targets of CDK inhibitors from CRISPR screens. Kimberly H. Kim, Pfizer inc., San Diego, CA
LBA012 Engineered mini-livers for high-throughput tumor organoid screening of prodrugs. Peyton J. Tebon, UCLA, Los Angeles, CA

LBA013 Phosphoproteomics reveals active drug targets on pathways of resistance and predicts response to midostaurin plus chemotherapy in FLT3 mutant-positive acute myeloid leukemia. Luis Veiga Nobre, Kinomica Ltd, Macclesfield, United Kingdom

LBA015 Accelerating clinically-translatable discoveries using a network-and RNA-based precision-oncology framework. Alessandro Vasciaveo, Columbia University Medical Center, New York, NY

LBA016 Androgen Receptor (AR) N-Terminus-Domain-Binding Small Molecule Degraders for the Treatment of AR Splice Variant-Positive Castration-Resistant Prostate Cancer. Ramesh Narayanan, University of Tennessee Health Science Center, Memphis, TN

LBA018 Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers. Israel Matos, KisoJi Biotechnology Inc., Toronto, ON, Canada

LBA019 The immune checkpoint protein BTN1A1 suppresses T cell activation through interactions with Gal9 and PD-1. Ezra M. Chung, STCube Pharmaceuticals, Gaithersburg, MD

LBA020 Targeting FGFR2c isoform, a novel therapeutic target with FGFR inhibitor in endometrial cancer. Asmerom Tesfamariam Senga, Queensland University of Technology (QUT)/Translational Research Institute (TRI), Brisbane, QLD, Australia

LBA021 Immune resistance interrogation study (IRIS): Initial report of next generation sequencing (NGS) results in patients with primary versus acquired resistance to anti-PD1/L1 antibodies. Sofia Genta, Princess Margaret Cancer Center, Toronto, ON, Canada

LBA022 IMM20324, a first-in-class, anti-interleukin-38 monoclonal antibody, rescues myeloid cell activation in vitro and induces robust anti-tumor responses in vivo. Benjamin C. Harman, Immunome, Inc., Exton, PA
LBA023 Regulation and function of ZEB1 dimerization in lung adenocarcinoma progression and metastasis. Mabel Perez-Oquendo, MD Anderson Cancer Center, Houston, TX

LBA024 IL-36γ induces immune infiltration and suppresses tumor growth in a syngeneic mouse model for pancreatic cancer. Kuntal Halder, The Translational Genomics Research Institute, Phoenix, AZ

LBA025 AXL-STAT3 targeting of lung tumor microenvironments. Josephine A. Taverna, UT Health San Antonio MD Anderson, San Antonio, TX

LBA026 Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients. Yogesh Bramhecha, IMV Inc., Dartmouth, NSW, Canada

LBA027 Mechanistic insights on the effects of the lead next generation galeterone analog, VNPP433-3β in castration resistant prostate cancer. Elizabeth Thomas, University of Maryland SOM, Baltimore, MD

LBA028 Small molecule inhibitor combined with Anti-PD1 cure glioblastoma and induce long term immunity. Jinan Behnan, Albert Einstein College of Medicine, Bronx, NY

LBA029 Development of computational tools for evaluating differential protein expression relative to spatial oxygen gradients using imaging mass cytometry. Mark Zaidi, University of Toronto, Toronto, ON, Canada

LBA030 DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model. Yves Fradet, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada

LBA031 Novel Synthetic Lethality Treatment for p53 Mutant Cancer. Andrei V. Bakin, Roswell Park Comprehensive Cancer Center, Buffalo, NY

LBA032 Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286. Tanya T. Kwan, Clovis Oncology, Inc., Boulder, CO
LBA033 YM155 induces DNA damage and cell death in anaplastic thyroid cancer cells by inhibiting DNA topoisomerase Iα at the ATP binding site. Ryan Mackay, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA

LBA034 Necrostatin-1 Protects Ferroptosis by xCT Induction in a RIPK1- and IDO-independent manner. Md Abdullah, Chungnam National University, Daejeon, Republic of Korea

LBA035 Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer: CANOPY-N Trial. Jay M. Lee, University of California, Los Angeles, Los Angeles, CA

LBA036 Whole-exome sequencing of germ cell tumors in childhood. Janaina Mello Soares Galvão, Barretos Cancer Hospital, Barretos, Brazil

LBA037 Reposition of the antibiotic nitroxoline as a novel STAT3 inhibitor for drug-resistant urothelial bladder cancer. WENFENG LIN, Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

LBA038 KontRASt-01: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation. Benjamin Solomon, Peter MacCallum Cancer Centre, Melbourne, Australia

LBA039 Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial. Edward B. Garon, David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, CA

LBA040 Genome-wide detection of enhancer-hijacking events in cancer genomes. Feng Yue, Northwestern University, Chicago, IL

LBA041 Identification and characterization of potent RAD51 inhibitors targeting RAD51-BRCA2 interaction. Sanjita Sasmal, Satyax Pharma Innovations Private Limited, Hyderabad, India
LBA042 Male Sex is an Independent Predictor of Recurrence-Free Survival in Middle Eastern Papillary Thyroid Carcinoma. KHAWLA S. AL-KURAYA, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

LBA043 mRNA expression of mTOR signaling components as potential predictive biomarker in pancreatic neuroendocrine neoplasms. Sebastian Wolfshoefer, Charité - University Medicine Berlin, Germany, Berlin, Germany

LBA044 Analysis in real clinical practice with durvalumab as consolidation therapy after chemoradiotherapy in unresectable locally advanced non-small-cell lung cancer. Blanca B. Távara, Complejo Asistencial Universitario de León, León, Spain

LBA045 Analysis in real clinical practice with durvalumab as consolidation therapy after chemoradiotherapy in unresectable locally advanced non-small-cell lung cancer: A comparative study of two cohorts. Blanca Távara, Complejo Asistencial de León, León, Spain

LBA046 Neoadjuvant and Adjuvant Capmatinib in Resectable Non-Small Cell Lung Cancer With MET Exon 14 Skipping Mutation or High MET Amplification: GEOMETRY-N Trial. Karen Kelly, UC Davis Comprehensive Cancer Center, Sacramento, CA

LBA047 Inhibition of c-Met pathway effective on liver cancer stem cell model. Said M. Afify, Graduate School of Interdisciplinary Science and Engineering in Health Systems Okayama University, Okayama, Japan

LBA048 Lymph node metastasis targeted intranodal delivery of docetaxel improves treatment outcome. Ariunbuyan Sukhbaatar, Tohoku University, Sendai, Japan

LBA049 Possibility of total body irradiations for lymph node metastasis and lung metastasis. Shouta Sora, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Japan

LBA050 Bioenergetic evaluation of Mito-compound Mito-Met as potent cytotoxic agents in gastric cancer. Giovanni A. Lineros Franco, Fundación Cardiovascular de Colombia, Floridablanca, Colombia
LBA051 Importance of drug osmotic pressure and viscosity for efficient drug delivery using lymphatic drug delivery system. Radhika Mishra, Tohoku University, Sendai, Japan

LBA052 Prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients. Fatima El agy, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, FEZ, Morocco

LBA053 Inhibitory Effects of Baicalein on Cell Proliferation in Breast Cancer Cells. Besa xhabija, University of Michigan-Flint, Flint, MI